ARTIS Ventures’ Post

Congratulations to Israeli Digital Health venture Nucleai for their remarkable achievement in raising $14 million in funding, led by Merck Group’s VC arm, M Ventures 🎉 Nucleai's groundbreaking work in leveraging AI and machine learning to analyse pathology images and spatial data at cellular and tissue levels. Their proprietary technology extracts detailed patterns and features from medical images, providing invaluable insights into the tumour microenvironment, cellular morphology, and spatial relationships between different cell types. This round, led by M Ventures, and support by existing investors, brings Nucleai's total funding to an impressive $60 million. Notable backers include S32, Sanofi Ventures, Debiopharm, 复星锐正资本 FOSUN RZ Capital , Vertex Ventures Israel, and Grove Ventures. With this new funding, Nucleai plans to deploy its AI algorithms for the prospective enrollment of patients in clinical trials—a pioneering move in personalized healthcare solutions tailored to each patient's unique needs. Founded in 2018, Nucleai is spearheaded by Avi Veidman, Eliron Amir, Lotan Chorev, and Albert Achtenberg. They bring expertise from their tenure managing the AI computer vision department in the Israeli military’s Intelligence Corps. This achievement underscores Israel's prowess in driving innovation at the intersection of technology and healthcare. 🌟 #DigitalHealth #Israel #fundingnews

Congrats to Dr. Julia Moosbauer, Dr. Franz MJ Pfister, MD, MBA, Paul Mayer, Michael Meyerhoff and team deepc, an AI-powered radiology startup, for securing $13 million in the Series A extension round, bringing the company’s total funding to date to $30 million. Now off to accelerating growth and international expansion, as well as further enhance and commercialise deepc‘s industry-leading operating system. DeepC‘s radiology AI platform deepcOS, provides clinicians with effortless access to a myriad of regulatory-approved AI solutions for more than 60 clinical indications, delivering more efficient workflows and assisting radiologists in their daily routine. By reducing the complexity and cost of deploying AI in radiology, deepc enhances diagnostic efficiency and accuracy, benefiting both healthcare providers and patients. The funding was co-led by Sofinnova Partners and Bertelsmann Investments, with participation from new investors KHP Ventures and SwissHealth Ventures, alongside existing investor Winning Mindset Ventures. #AI #startup #tech #innovation #funding #captablediversity #venturecapital

PictorLabs Inc an AI-driven histopathology startup, has secured $30 million in Series B funding… To scale its “Virtual Staining” technology. Here’s the TL;DR: 1. Funding Round: Led by Insight Partners with participation from M Ventures, PictorLabs’ new funding brings their total raised to $48.8 million. This capital will be used to expand the team and bring their groundbreaking technology to more labs. 2. Virtual Staining Tech: PictorLabs digitizes the staining process used in analyzing tissue samples, eliminating the need for repeated manual washing and staining. This AI-based approach speeds up diagnoses for conditions like cancer and infectious diseases, enhancing efficiency and consistency in pathology labs. 3. AI in Healthcare: Despite AI's potential to reduce human error and improve diagnostics, adoption remains low due to concerns over liability and trust. However, companies like PictorLabs are pushing boundaries to make AI more mainstream in medical diagnostics. Follow Brian Com for More…
 Read the latest Ai101x Newsletter (link in bio) #AI #automation #artificialintellence

Pumped to lead this round in UnityAI and the stellar Edmund Jackson.! Unity.AI is Max Ventures' first healthcare investment out of our new fund and will leverage proprietary AI (actually) to help improve patient flow and care orchestration. Recently, hospital CIOs and CDOs (Edmund was the former CDO at HCA Healthcare, the nation's largest for-profit system) have told me there's prominent and urgent use cases for emerging technology (#ai, #genai, and more) to address major administrative and non-clinical problems in the hospital setting. Unity.AI's solution supports that sentiment and we are actively on the lookout for entrepreneurs solving problems in this vein! https://lnkd.in/dbWXEiXN

Mumbai-based AI diagnostics startup, Qure.ai, has successfully raised $65 million in a Series D funding round led by Lightspeed Venture Partners and 360 ONE Asset Management. The round saw participation from new investors, including Merck & Co.’s Merck Global Health Innovation Fund and Kae Capital, alongside existing investors such as Novo Holdings, HealthQuad, and TEAMFund. The fresh capital will be utilized to accelerate Qure.AI’s expansion into the US and other international markets, further develop its generative AI foundation models, and pursue strategic acquisitions. Qure.AI, specializes in using artificial intelligence to detect and manage critical diseases. Its products are already in use at over 3,000 imaging sites in more than 90 countries and have received clearance from both US and European Union regulators. Qure.AI’s solutions are designed to enhance diagnostic accuracy and efficiency, often surpassing the capabilities of human radiologists and physicians in identifying conditions such as tuberculosis, lung cancer, and stroke. Founder: Prashant Warier Follow Rise & Shine for daily funding deals. Stay ahead, stay motivated with www.riseshine.in #ai #startup #funding

Unlearn.AI has successfully raised $50M in a Series C round led by Altimeter Capital, with significant contributions from Radical Ventures, Wittington Ventures, Mubadala Capital, EPIC Ventures, and Necessary Ventures Capital. This milestone enables Unlearn to further its groundbreaking work in AI for clinical trials, notably through the development of digital twins that promise to streamline and enhance the efficiency of these crucial studies. This funding not only supports Unlearn's growth and expansion into new therapeutic areas but also underscores the potential of AI to transform medical research by making it more efficient and effective. https://lnkd.in/eSd3UAtY #UnlearnAI #ClinicalTrials #DigitalTwins #AIInHealthcare #SeriesCFunding

Medtech startup Qure.ai has raised $65 Mn (INR 543 Cr) in a Series D funding round: 1️⃣ The round was co-led by Lightspeed Venture Partners and 360 ONE Asset Management. 2️⃣ Additional participants include Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, HealthQuad, and TEAMFund. 3️⃣ The funding will support expansion in the US and other markets, improve GenAI models, and finance acquisitions. 4️⃣ Qure.ai, founded in 2016 by Prashant Warier, uses AI for medical imaging diagnostics, detecting brain trauma and chest diseases. 5️⃣ Its #AI algorithms can analyze X-rays, CT Scans, and MRIs faster than doctors. 6️⃣ CEO Prashant Warier highlighted AI’s role in overcoming healthcare challenges, from drug discovery to patient management and surgical robotics. #EntrepreneurshipStudio #QureAI #StartupNews #FundingNews

Congratulations to the founders of immunitoAI, Aridni Shah and Trisha Chatterjee! Founded in 2020, immunitoAI is revolutionizing the field of antibody discovery with their innovative use of artificial intelligence. By leveraging AI, they aim to expedite the traditionally lengthy and costly process of drug discovery, reducing the average time from 4-5 years to just 11-12 months. Their vision to make healthcare more agile and cost-effective is truly inspiring. Their journey began with Entrepreneur First’s talent program, which brought these brilliant minds together. Their combined expertise in biology and computer science has been pivotal in overcoming industry skepticism towards AI in biology. Securing $1 million in seed funding led by pi Ventures, with participation from Entrepreneur First, is a testament to their groundbreaking approach and the potential they hold to transform the biotech industry. immunitoAI’s commitment to reducing drug discovery time and costs, while maintaining scientific rigor, is setting a new benchmark in precision therapeutics. As they continue to innovate and push boundaries, OwnDesk wishes the entire team and founders all the best for their future endeavors. Rajashree Kadam Suman Sengupta Sambuddha Sen Paulomi Sanghavi Nimesh Agrawal Sarath Mohan Devendra Singh Chundawat Abhishek Jhade Abhishek Jain Yash Rathore Dhruv Mangal Anwesha Paul Srushti Kore #aiinhealthcare #biotechinnovation #antibodydiscovery #startupsuccess #healthcarerevolution #immunitoAI #AI #AIpowered #biology #startup #bangalore

🌟 Meet Our Chief Technology Officer (CTO), Fredrik P. 🌟   As our CTO, Fredrik leads technical development and strategy with a focus on our product, Dermalyser. He also helps us navigate the complexities of regulatory compliance within the MedTech field.    When asked about his decision to join AI Medical Technology (AMT), Fredrik reveals, "I found AMT to be a really interesting company and using AI and machine learning to diagnose skin cancer is one of the most intriguing applications for this technology I've seen so far."   Fredrik likes the vibrant start-up environment, and working with innovation and technology at the forefront has always attracted him. With a wealth of experience spanning both large companies and startups, AMT marks Fredrik's fourth startup position.    Looking ahead, Fredrik sees a promising future for skin cancer diagnostics. He believes that AI-driven support will continue to evolve, offering increasingly sophisticated diagnostic capabilities and advanced functionalities. Fredrik is optimistic that these developments will not only enhance accuracy but also alleviate the need for certain invasive and costly procedures.

July 27 2024 – 5 Notable Articles To Read Article: Artiva Biotherapeutics Announces Pricing of Upsized $167.0M Initial Public Offering Takeaway: A biotechnology company at the clinical stage, dedicated to developing effective, safe, and accessible cell therapies for patients suffering from severe autoimmune diseases and cancers. Source: GlobeNewswire Link: https://lnkd.in/driqTcHj Article: Funding surge for blank cheque companies points to Spac bounceback Takeaway: An investment class once written off due to early excesses and poor performance is now showing signs of revival. Source: Financial Times Link: https://lnkd.in/dZa_XGx7 Article: Informa agrees to buy Cannes Lions owner Ascential for almost £1.2B Takeaway: The acquisition of Ascential marks the completion of Informa's three-year investment program, which has strengthened its position as the world's largest events business. Source: Financial Times Link: https://lnkd.in/dsHnARte Article: VCs are still pouring billions into generative AI startups Takeaway: According to Crunchbase data, if the current trend continues, generative AI companies are set to match or surpass the approximately $21.8B raised in 2023. The breakdown of the H1 2024 total by stage is as follows: 198 angel/seed deals amounting to $500Mn, 39 early-stage deals totaling $8.7B, and 18 late-stage deals reaching $3.1B. Source: TechCrunch Link: https://lnkd.in/dPADfDt7 Article: National Basketball Association (NBA) Announces $77B TV and Streaming Deals with Amazon, The Walt Disney Company and NBCUniversal Takeaway: The new 11-year agreements, set to last through the 2035-2036 season, will have Disney paying the NBA an average of $2.6B per year, a significant increase from the $1.5B per year under the current deal. Source: The Information Link: https://lnkd.in/dRPU8cSq #news #research #ai #business